Efficient biologics drug development platform

Sunflower Therapeutics is pioneering advancements in protein manufacturing through its innovative Daisy Petal™ Perfusion Bioreactor System. This fully automated, benchtop bioreactor is designed for continuous protein production, utilizing a unique in-vessel perfusion method that allows for the continuous feeding of biomass and harvesting of secreted proteins. The system is engineered to simplify the protein production process, making it accessible to both seasoned bioprocessing experts and newcomers. With the support of its HelianthOS™ software, users can navigate the entire process from setup to protein harvesting with minimal training, thereby enhancing efficiency and consistency in protein yields.

In addition to the Daisy Petal™, Sunflower Therapeutics also offers the Dahlia Petal™ Perfusion Bioreactor System, which facilitates the transition from small-scale research to larger-scale production. This system is designed to minimize contamination risks and incorporates single-use components, making it a flexible solution for scaling biomanufacturing efforts. By lowering the barriers to protein production, Sunflower Therapeutics aims to democratize biomanufacturing, enabling researchers and organizations to contribute to advancements in medicine, synthetic biology, and other fields without the need for extensive infrastructure or specialized expertise.

United States

Sunflower Therapeutics is a unique biotechnology start-up focused on dramatically reducing the time and cost to develop and manufacture biologics for patients around the world. With a genetically-optimized host, data-driven process development, and a novel, ‘right-sized’ manufacturing unit, the experienced Sunflower team is creating an efficient, patient-centered, end-to-end drug production platform that we plan to deploy worldwide.

Sunflower Therapeutics

Company Details